The Case of the Vanishing Blots: How Simufilam's Evidence Disappeared
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
The Case of the Vanishing Blots: How Simufilam's Evidence Disappeared
-
ナレーター：
-
著者：
A single set of laboratory photographs - western blots - became the fulcrum of a dispute that touched federal grand juries, NIH funding, and hundreds of Alzheimer’s patients. Pixels matching across images from supposedly separate experiments, an outside lab that turned out to be the same academic group behind the drug, and a night-before-trial DOJ decision leave one central question: how did the visual evidence underpinning simufilam vanish into ambiguity?
In this episode, we trace the chronology of simufilam’s rise and the contested data that sustained it, laying out the key players, the published papers, and the discovery that blurred the line between independent confirmation and internal reanalysis. What does the record show about the provenance of the western blots, and why did four federal investigations still not resolve that question?
Person: Hoau-Yan Wang
Person: Lindsay Burns
Person: Thomas Südhof
Date: September 2020
Event: Re-analysis of biomarker data presented as from an outside laboratory
- Cassava Sciences announced an outside laboratory confirmed simufilam’s biomarker improvements in September 2020.
- The “outside laboratory” that re-analyzed the failed May 2020 cerebrospinal fluid biomarkers was Wang’s CUNY lab.
- Simufilam (PTI-125) was built on findings about filamin A (FLNA) reported in PLOS One papers co-authored by Wang, Burns, and Maya Frankfurt.
- NIH funding was awarded in 2018 and open-label studies began in March 2020 for simufilam.
- Four simultaneous federal investigations occurred and the original laboratory data was never produced, leaving no court-established guilt or institutional proof of misconduct.
To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.
© 2026 OBOMEDIA. All rights reserved.
This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません